Information Provided By: 
Fly News Breaks for October 21, 2019
FOMX
Oct 21, 2019 | 07:17 EDT
Foamix Pharmaceuticals last week arguably the most successful week in its history as a public company, with FMX101 being approved by the FDA for treatment of moderate-to-severe acne vulgaris and FMX103 being accepted for review by the agency as a treatment for moderate-to-severe papulopustular rosacea, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on the shares and boosted his price target to $11 from $10.
News For FOMX From the Last 2 Days
There are no results for your query FOMX
